Aminocaproic acid clinical pharmacology: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Aminocaproic acid}} {{CMG}}; {{AE}} {{SS}} ==Clinical Pharmacology== The fibrinolysis-inhibitory effects of AMICAR appear to be exerted principally via inhibition...")
 
(Redirected page to Aminocaproic acid#Pharmacology)
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Aminocaproic acid#Pharmacology]]
{{Aminocaproic acid}}
{{CMG}}; {{AE}} {{SS}}
 
==Clinical Pharmacology==
The fibrinolysis-inhibitory effects of AMICAR appear to be exerted principally via inhibition of [[plasminogen activator]]s and to a lesser degree through antiplasmin activity.
 
In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1). Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.
 
After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD). Correspondingly, the volume of distribution after intravenous administration has been reported to be 30.0 ± 8.2 L. After prolonged administration, AMICAR has been found to distribute throughout extravascular and intravascular compartments of the body, penetrating human red blood cells as well as other tissue cells.
 
Renal excretion is the primary route of elimination. Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid. Renal clearance (116 mL/min) approximates endogenous creatinine clearance. The total body clearance is 169 mL/min. The terminal elimination half-life for AMICAR is approximately 2 hours.<ref>{{Cite web  | last =  | first =  | title = DailyMed: Search | url = http://dailymed.nlm.nih.gov/dailymed/search.cfm?startswith=Aminocaproic+acid&x=-1148&y=-229 | publisher =  | date =  | accessdate = 31 January 2014 }}</ref>
 
==References==
 
{{Reflist|2}}
 
[[Category:Antifibrinolytics]]
[[Category:Cardiovascular Drugs]]
[[Category:Amino acids]]
[[Category:Antifibrinolytics]]
[[Category:Hematology]]
 
[[ja:Ε-アミノカプロン酸]]
[[pl:Kwas ε-aminokapronowy]]
 
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 15:33, 21 July 2014